A20 As a Potential Therapeutic Target for COVID-19

Overview

Journal Immun Inflamm Dis

Date 2025 Jan 24

PMID 39853876

Authors

Yongyao Wu

Lilan He

Rong Li

Jiuxuan Li

Qing Zhao

Bin Shao

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID-19 may exhibit immunosuppression in the initial stage of infection, while a cytokine storm can occur when the disease progresses to a severe stage. This inopportune immune rhythm not only makes patients more susceptible to the virus but also leads to numerous complications resulting from the excessive production of inflammatory factors. A20, which is widely accepted as a pivotal regulator of inflammation, has been shown to be implicated in the processes of antiviral responses and immunosuppression. Thus, A20 may participate in regulating the pathological processes of COVID-19.

Methods: This narrative literature review summarizes recent evidence on the mechanisms of A20 in regulating the pathological processes of COVID-19. We also downloaded single-cell RNA-seq data sets from healthy individuals and patients with varying severities of COVID-19 from the NCBI GEO database to further dissect A20's regulatory mechanisms of these intricate cytokine pathways that are closely associated with SARS-CoV-2 infection.

Results: A20 might be one of the most critical anti-infectious and anti-inflammatory factors involved in the pathogenesis of COVID-19. It effectively suppresses the immune damage and inflammatory storm caused by viral infection.

Conclusions: Understanding the relationship between A20-regulated signaling pathways and pathological processes of COVID-19 can provide insight into potential targets for intervention. Precise regulation of A20 to induce antiviral activity and an anti-inflammatory response could mediate the pathogenesis of COVID-19 and could become an effective treatment.

References

Shemesh M, Aktepe T, Deerain J, McAuley J, Audsley M, David C . SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoS Pathog. 2021; 17(8):e1009800. PMC: 8389490. DOI: 10.1371/journal.ppat.1009800. View

Won T, Gilotra N, Wood M, Hughes D, Vladut Talor M, Lovell J . Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination. Front Immunol. 2022; 13:851620. PMC: 8894592. DOI: 10.3389/fimmu.2022.851620. View

Weinlich R, Oberst A, Beere H, Green D . Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2016; 18(2):127-136. DOI: 10.1038/nrm.2016.149. View

Maelfait J, Roose K, Vereecke L, Mc Guire C, Sze M, Schuijs M . A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection. PLoS Pathog. 2016; 12(1):e1005410. PMC: 4731390. DOI: 10.1371/journal.ppat.1005410. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Arguello M, Paz S, Ferran C, Moll H, Hiscott J . Anti-viral tetris: modulation of the innate anti-viral immune response by A20. Adv Exp Med Biol. 2014; 809:49-64. DOI: 10.1007/978-1-4939-0398-6_4. View

Jandhyala D, Thorpe C, Magun B . Ricin and Shiga toxins: effects on host cell signal transduction. Curr Top Microbiol Immunol. 2011; 357:41-65. PMC: 7120278. DOI: 10.1007/82_2011_181. View

Zhang B, Nandakumar R, Reinert L, Huang J, Laustsen A, Gao Z . STEEP mediates STING ER exit and activation of signaling. Nat Immunol. 2020; 21(8):868-879. PMC: 7610351. DOI: 10.1038/s41590-020-0730-5. View

10.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

11.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

12.

Wang W, Chen J, Yu X, Lan H . Signaling mechanisms of SARS-CoV-2 Nucleocapsid protein in viral infection, cell death and inflammation. Int J Biol Sci. 2022; 18(12):4704-4713. PMC: 9305276. DOI: 10.7150/ijbs.72663. View

13.

Dickey T, Song B, Pyle A . RNA binding activates RIG-I by releasing an autorepressed signaling domain. Sci Adv. 2019; 5(10):eaax3641. PMC: 6774723. DOI: 10.1126/sciadv.aax3641. View

14.

Oliviero A, de Castro F, Coperchini F, Chiovato L, Rotondi M . COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?. Neuroscientist. 2020; 27(3):214-221. DOI: 10.1177/1073858420939033. View

15.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

16.

Sierra B, Perez A, Aguirre E, Bracho C, Valdes O, Jimenez N . Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1. Open Forum Infect Dis. 2020; 7(10):ofaa407. PMC: 7499702. DOI: 10.1093/ofid/ofaa407. View

17.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

18.

Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U . A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol. 2009; 182(12):7718-28. DOI: 10.4049/jimmunol.0803313. View

19.

Czerkies M, Korwek Z, Prus W, Kochanczyk M, Jaruszewicz-Blonska J, Tudelska K . Cell fate in antiviral response arises in the crosstalk of IRF, NF-κB and JAK/STAT pathways. Nat Commun. 2018; 9(1):493. PMC: 5799375. DOI: 10.1038/s41467-017-02640-8. View

20.

Patel A, Jernigan D . Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(5):140-146. PMC: 7004396. DOI: 10.15585/mmwr.mm6905e1. View